Evidence map›Paper›PMID 37642764›Full record

ArticleClinical rheumatology2024

Antibodies against oxidized LDL and atherosclerosis in rheumatoid arthritis patients treated with biological agents: a prospective controlled study.

G V Papamichail, A N Georgiadis, C C Tellis, I Rapti, T E Markatseli, V G Xydis, A D Tselepis, A A Drosos, P V Voulgari

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

G V PapamichailDepartment of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0009-0007-5297-1705
A N GeorgiadisRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.ORCID https://orcid.org/0000-0002-9561-6355
C C TellisAtherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0000-0002-3959-1544
I RaptiDepartment of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0000-0003-1735-5839
T E MarkatseliRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.ORCID https://orcid.org/0000-0001-7330-5428
V G XydisDepartment of Radiology, Medical School, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0000-0002-1475-9021
A D TselepisAtherothrombosis Research Centre/Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Ioannina, Greece.ORCID https://orcid.org/0000-0002-5854-2385
A A DrososRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.ORCID https://orcid.org/0000-0002-2232-0326
P V VoulgariRheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece. pvoulgar@uoi.gr.ORCID http://orcid.org/0000-0002-5193-2284
University of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of this study was to investigate the relation among atherosclerosis, antibodies against oxidized LDL (anti-oxLDL), and inflammation in rheumatoid arthritis (RA) patients treated with biological (b) disease-modifying anti-rheumatic drugs (DMARDs).

methodsFifty-nine patients who were receiving conventional synthetic DMARDs and were eligible for treatment with a biological agent were included in the study. Total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and IgG antibodies against oxidized LDL (anti-oxLDL) as well as carotid intima-media thickness (cIMT) were determined before and after 6 months of treatment. Thirty-one healthy individuals were used as a control group.

resultsAt baseline, RA patients had lower TC and HDL-C levels and increased cIMT compared to controls. After a 6-month follow-up, the re-evaluation of carotids revealed a statistically important decrease of cIMT values. This observation was accompanied by a statistically important elevation of HDL-C levels and a reduction of the titer of anti-oxLDL antibodies regardless of the bDMARD that was administered. No statistically significant association was found between the cIMT and anti-oxLDL, HDL-C, CRP, or DAS28 score neither before nor 6 months after treatment using linear regression analyses adjusted for age and gender.

conclusionsWe provide evidence that atherogenic lipid profile and ongoing atherosclerosis which characterize RA patients appear to improve after biological therapy, and we also suggest a possible atherogenic effect of IgG anti-ox LDL antibodies.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAtherosclerosisCarotid Intima-Media ThicknessCholesterol, HDLCholesterol, LDLHumansImmunoglobulin GLipoproteins, LDLProspective StudiesAntirheumatic AgentsCholesterol, HDLCholesterol, LDLImmunoglobulin GLipoproteins, LDLoxidized low density lipoproteinAntibodies against oxidized LDL atherosclerosisBiologic agentsCardiovascular riskIntima-media thicknessRheumatoid arthritis

Identifiers

PMID37642764
OpenAlexW4386256585

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.